Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans
about
pH signaling in human fungal pathogens: a new target for antifungal strategiesRapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TORIn vitro and in vivo activities of ruthenium(II) phosphine/diimine/picolinate complexes (SCAR) against Mycobacterium tuberculosisAntifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia speciesCryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortalityCalcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis.Calcineurin governs thermotolerance and virulence of Cryptococcus gattii.Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative.Stimulation of chitin synthesis rescues Candida albicans from echinocandins.Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans.Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins.Signal transduction cascades regulating fungal development and virulence.Calcineurin is essential for survival during membrane stress in Candida albicans.Essential role of calcineurin in response to endoplasmic reticulum stress.Application of caspofungin in China compared with amphotericin B and fluconazole.Regulatory circuitry governing fungal development, drug resistance, and disease.Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplantCaspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosisThe Crz1/Sp1 transcription factor of Cryptococcus neoformans is activated by calcineurin and regulates cell wall integrity.Characterization of the bafilomycin biosynthetic gene cluster from Streptomyces lohii.Systems-level antimicrobial drug and drug synergy discovery.Multiple signaling pathways regulate yeast cell death during the response to mating pheromones.Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.Caspofungin: first approved agent in a new class of antifungals.The Cryptococcus neoformans MAP kinase Mpk1 regulates cell integrity in response to antifungal drugs and loss of calcineurin functionA flucytosine-responsive Mbp1/Swi4-like protein, Mbs1, plays pleiotropic roles in antifungal drug resistance, stress response, and virulence of Cryptococcus neoformans.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literatureMitogen-activated protein kinase stimulation of Ca(2+) signaling is required for survival of endoplasmic reticulum stress in yeast.In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methodsThe echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.The pharmacology and clinical use of caspofungin.Nonapoptotic death of Saccharomyces cerevisiae cells that is stimulated by Hsp90 and inhibited by calcineurin and Cmk2 in response to endoplasmic reticulum stresses.Combination therapeutic approaches for the management of invasive aspergillosis in organ transplant recipients.Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistanceIn vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.Kch1 family proteins mediate essential responses to endoplasmic reticulum stresses in the yeasts Saccharomyces cerevisiae and Candida albicans.In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.Antifungal adjuvants: Preserving and extending the antifungal arsenal
P2860
Q26830123-89B6B9AB-AA0A-49AE-862B-AABBE4DCC5B0Q28361576-1C5479D3-C12D-42BF-847D-C94F20C5F909Q28533382-A176A313-0140-40C3-9D0C-714C580D2FB3Q28769637-200F2624-44C8-455C-841C-8FD7765DB546Q30438524-414645C8-E4E9-4E9A-B8C5-CC111CDBB652Q30441628-13A8D7AE-F59A-4BF0-B54B-936FD1C27939Q30536858-4A40623D-1FB1-4856-BFA8-319892E313D8Q33200348-26479E45-CD57-4039-B5A3-A1A5A7CD5222Q33326983-863260E4-C51A-4754-8AC3-F48069E51363Q33593689-3996D7BE-43C4-4305-A945-DDF4CBAFD413Q33805542-DFB8E8F0-B578-4159-9E5C-E80BF02FA7EBQ33883762-0523EC17-EDA6-434E-A294-6432D78B9EC9Q34010291-1615596A-30F5-4319-B563-A4A4DA45F0A9Q34085830-62E1242C-749F-4A1C-AE1C-809B0D3DEBC2Q34087957-403D916A-2BB9-4B47-9CFD-21B6F8E59029Q34182814-4A0DCAAE-5F3A-43E3-A15E-0FE79CF62B73Q34190284-C0D9CB1E-AA5F-44F6-AC3D-EAD1EFCE2C96Q34399223-7DD2A59A-E136-47A8-AD8C-C6AD77B885A3Q34481664-43D62884-F055-41D4-A22F-57E17BB54578Q34513852-641FF160-BD68-431F-8B57-000FA9688C62Q34516564-7EA80E28-074E-468B-ACA6-9E7DAFAB80F7Q34567302-218B5ACE-BD96-4B59-9AE6-5864D9D33239Q34626969-14B4EDE0-E2E5-45D8-8F25-24A598338F74Q34886111-17BE23B3-D707-4D5C-93BA-F0F082C0663BQ35092521-4A86B686-F6AA-47AD-B74E-C09C8484BF13Q35124726-A3CE9077-193E-4E5F-950A-0DC9970F2E1BQ35128586-067FD1FD-A379-4286-AADD-847ACD9F79CCQ35666161-CC340F4E-6AB4-435E-8106-1246AC103D9AQ35959484-423B766B-5939-40A4-A86B-75DF261895F8Q36125241-561A62C2-776D-4B5D-B555-B04DAEE17B90Q36425093-97284F8B-F49D-49AD-8FE3-0D16647DBF0EQ36626518-018ADF81-62AF-4A06-9071-8AA845AEA36FQ36788428-D68E3617-4CE2-40C6-AE26-0BA76BA948BEQ36994306-4D8FCB6A-91D8-4799-9C2B-2882B2474EF6Q37078394-D7CC2635-CBD8-4DE0-B147-16C4A943926EQ37122826-36CB1767-E286-4217-B6DB-D80C43395D5FQ37274705-D233CACD-B554-435B-AF77-5465D8790B40Q37349001-46E32F1D-8BA4-44A1-AE8F-311838282B8CQ37625139-B6B224B2-A83E-4EB7-AEC9-0CEA8E224598Q37705308-267CEB2C-5FEC-42CE-9254-DDBF06D56BD6
P2860
Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Synergistic antifungal activit ...... gainst Cryptococcus neoformans
@ast
Synergistic antifungal activit ...... gainst Cryptococcus neoformans
@en
Synergistic antifungal activit ...... gainst Cryptococcus neoformans
@nl
type
label
Synergistic antifungal activit ...... gainst Cryptococcus neoformans
@ast
Synergistic antifungal activit ...... gainst Cryptococcus neoformans
@en
Synergistic antifungal activit ...... gainst Cryptococcus neoformans
@nl
prefLabel
Synergistic antifungal activit ...... gainst Cryptococcus neoformans
@ast
Synergistic antifungal activit ...... gainst Cryptococcus neoformans
@en
Synergistic antifungal activit ...... gainst Cryptococcus neoformans
@nl
P2093
P2860
P1476
Synergistic antifungal activit ...... gainst Cryptococcus neoformans
@en
P2093
J R Perfect
M Del Poeta
M E Cardenas
P2860
P304
P356
10.1128/AAC.44.3.739-746.2000
P407
P577
2000-03-01T00:00:00Z